In a significant development at a recent public hearing with Commission III of the Indonesian House of Representatives in Jakarta, Professor Musri Musman, Chairperson of the Sativa Foundation Trustee and a respected researcher from Syiah Kuala University, presented compelling evidence supporting the therapeutic potential of CBD (cannabidiol) oil for treating cerebral palsy.
During his presentation, Professor Musman highlighted the interaction between CBD oil and the brain’s neurological pathways. He explained how CBD, a non-psychoactive compound derived from the cannabis plant, can modulate the communication between CB1 and CB2 nerve receptors in the brain and peripheral nervous system. This interaction, he suggests, could play a key role in enhancing neural functions in individuals with cerebral palsy.
The discourse on CBD’s potential benefits was fueled by a recent viral story of a mother, Santi Warastuti, who has been advocating for the legalization of medical marijuana to help manage her child’s cerebral palsy symptoms. Her story has ignited a broader discussion on the subject within Indonesia, drawing attention to the need for more progressive treatments in managing such conditions.
Professor Musman also clarified concerns regarding dosage and safety, noting that daily doses ranging from 300 milligrams to 600 milligrams have been found effective and safe, showing no signs of addiction or intoxication in patients. He stated that dosages up to 1,500 milligrams per day are considered safe for individuals with cerebral palsy, according to the research findings.
This groundbreaking discussion at the Senayan Parliament Complex points to a possible shift in treatment paradigms for cerebral palsy, emphasizing a more personalized approach to dosage and administration of CBD oil, tailored to individual needs. As Indonesia grapples with its policies on medical cannabis, testimonies and research like Professor Musman’s play a crucial role in shaping future legislation and healthcare strategies.